Literature DB >> 29390067

Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).

A C Lockhart, C E Reed, P A Decker, B F Meyers, M K Ferguson, A R Oeltjen, J B Putnam, S D Cassiv, A J Montero, T E Schefter.   

Abstract

Entities:  

Year:  2019        PMID： 29390067      PMCID： PMC6386025          DOI： 10.1093/annonc/mdx813

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer.

Authors:  Lian Deng; Xiongjie Zhu; Zhongjian Yu; Ying Li; Lingyu Qin; Zhile Liu; Longbao Feng; Rui Guo; Yanfang Zheng
Journal:  Int J Nanomedicine       Date:  2020-10-09

Review 2.  The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.

Authors:  Dan Han; Baosheng Li; Qian Zhao; Hongfu Sun; Jinling Dong; Shaoyu Hao; Wei Huang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.